Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $69,484.59 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Denali Therapeutics Trading Down 10.1 %

NASDAQ:DNLI opened at $19.10 on Friday. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -6.92 and a beta of 1.39. The company’s 50-day moving average is $24.13 and its two-hundred day moving average is $24.83.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm earned ($0.72) EPS. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNLI. Rhumbline Advisers raised its position in shares of Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock worth $4,525,000 after buying an additional 22,900 shares during the period. TD Asset Management Inc increased its position in shares of Denali Therapeutics by 4.5% in the second quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock worth $4,160,000 after acquiring an additional 7,766 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Denali Therapeutics by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock valued at $769,000 after acquiring an additional 2,730 shares during the period. American Century Companies Inc. lifted its holdings in shares of Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after acquiring an additional 63,058 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock worth $32,913,000 after purchasing an additional 84,522 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on DNLI. HC Wainwright reduced their price objective on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday. William Blair began coverage on shares of Denali Therapeutics in a research report on Friday, January 3rd. They set an “outperform” rating for the company. JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday. Robert W. Baird assumed coverage on Denali Therapeutics in a report on Tuesday. They set an “outperform” rating and a $31.00 price objective for the company. Finally, Baird R W raised Denali Therapeutics to a “strong-buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.